Literature DB >> 21129312

[A clinical comparative study on Traditional Chinese Medicine serving as consolidation treatment in patients with advanced non-small cell lung cancer].

Jinhan Li1.   

Abstract

BACKGROUND: The role of Traditional Chinese Medicine(TCM) is recognized in treatment of non-small cell lung cancer.The aim of this study is to evaluate the efficacy of TCM serving as consolidation treatment in patients with advanced non-small cell lung cancer.
METHODS: One hundred and sixty-two patients with advanced non-small cell lung cancer were divided into two arms.Arm A(observation arm):81 cases,TCM serving as consolidation treatment after conventional treatment;Arm B(control arm):81 cases,only conventional treatment,no TCM serving as consolidation treatment.The TCM was given according mainly to the syndrome differentiation.Four types were found in the arm A:lung and spleen-qi deficiency type,the lung heat and phlegm-dampness type,the lung-yin and stomach-yin deficiency type,and the qi stagnation with blood stasis type.
RESULTS: 1-,2-,3-and 5-year survival rate accounted for 70.3%,37.0%,20.9% and 8.6% in arm A,and 61.7%,20.9%,8.6% and 3.7% in arm B,respectively.Median survival time was 18 months in arm A and 12 months in arm B,respectively.Statistically,2-and 3-year survival rate of arm A and arm B had significant difference(P < 0.05).
CONCLUSIONS: TCM serving as consolidation treatment in patients with advanced non-small cell lung cancer might be closely related to 2-and 3-year survival rate and median survival time improvement,but not to 5-year survival rate.

Entities:  

Year:  2007        PMID: 21129312     DOI: 10.3779/j.issn.1009-3419.2007.06.15

Source DB:  PubMed          Journal:  Zhongguo Fei Ai Za Zhi        ISSN: 1009-3419


  5 in total

1.  Oral Chinese herbal medicine as maintenance treatment after chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis.

Authors:  Q Wang; Q Wang; S F Wang; L J Jiao; R X Zhang; Y Zhong; J Zhang; L Xu
Journal:  Curr Oncol       Date:  2017-08-31       Impact factor: 3.677

2.  Long-Term Effectiveness of Combined Treatment with Traditional Chinese Medicine and Western Medicine on the Prognosis of Patients with Lung Cancer.

Authors:  Woung-Ru Tang; Sien-Hung Yang; Chih-Teng Yu; Chin-Chou Wang; Sheng-Teng Huang; Tzu-Hsin Huang; Ming-Chu Chiang; Yue-Cune Chang
Journal:  J Altern Complement Med       Date:  2016-03       Impact factor: 2.579

3.  Health Resource Utilization in Patients with Advanced Non-Small Cell Lung Cancer Receiving Chemotherapy in China.

Authors:  Jing Shi; Jun Zhu
Journal:  Clin Drug Investig       Date:  2016-01       Impact factor: 2.859

Review 4.  The possibility of traditional chinese medicine as maintenance therapy for advanced nonsmall cell lung cancer.

Authors:  Weiru Xu; Guowang Yang; Yongmei Xu; Qing Zhang; Qi Fu; Jie Yu; Mingwei Yu; Wenshuo Zhao; Zhong Yang; Fengshan Hu; Dong Han; Xiaomin Wang
Journal:  Evid Based Complement Alternat Med       Date:  2014-08-04       Impact factor: 2.629

5.  Modified Sijunzi Decoction Inhibits Epithelial-Mesenchymal Transition of Non-Small Cell Lung Cancer by Attenuating AKT/GSK3β Pathway in vitro and in vivo.

Authors:  Niu Shao; Yao Xiao; Jiaxin Zhang; Yuying Zhu; Shenglong Wang; Suzhen Bao
Journal:  Front Pharmacol       Date:  2022-01-17       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.